Hasan Farhad M, Alsahli Mazen, Gerich John E
University of Virginia School of Medicine, Charlottesville, VA, USA.
University of Toronto Faculty of Medicine, Toronto, Ontario, Canada.
Diabetes Res Clin Pract. 2014 Jun;104(3):297-322. doi: 10.1016/j.diabres.2014.02.014. Epub 2014 Mar 11.
The kidney plays an important role in glucose homeostasis via its production, utilization, and, most importantly, reabsorption of glucose from glomerular filtrate which is largely mediated via the sodium glucose co-transporter 2 (SGLT2). Pharmacological inhibition of SGLT2 increases urinary glucose excretion and decreases plasma glucose levels in an insulin-independent manner. Agents that inhibit SGLT2 represent a novel class of drugs, which has recently become available for treatment of type 2 diabetes. This article summarizes the rationale for use of these agents and reviews available clinical data on their efficacy, safety, and risks/benefits.
肾脏通过对葡萄糖的生成、利用，以及最重要的是从肾小球滤液中重吸收葡萄糖，在葡萄糖稳态中发挥重要作用，这一过程主要由钠-葡萄糖协同转运蛋白2（SGLT2）介导。对SGLT2的药理抑制可增加尿糖排泄，并以不依赖胰岛素的方式降低血糖水平。抑制SGLT2的药物代表了一类新型药物，最近已可用于治疗2型糖尿病。本文总结了使用这些药物的理论依据，并综述了关于其疗效、安全性及风险/获益的现有临床数据。
